Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653269 | 0.85 | PARP1 (0.38) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL12618985 | 0.85 | PARP1 (0.38) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL18248932 | 0.81 | PARP1 (0.36) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL18248941 | 0.80 | PARP1 (0.33) | PARP1 | |
| SCHEMBL18248875 | 0.78 | PARP1 (0.40) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL663849 | 0.78 | PARP1 (0.56) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7358641 | 0.77 | PARP1 (0.54) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL18225544 | 0.77 | PARP1 (0.31) | PARP1 | |
| SCHEMBL2646903 | 0.75 | PARP1 (0.41) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL18248911 | 0.74 | PBK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | PARP1 566/4885PDPK1 1433/4885CA12 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.